×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Yahoo Finance
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines...
1 month ago
NT219 Plus Cetuximab Demonstrates Efficacy, Tolerability in SCCHN
OncLive
NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and...
1 month ago
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
Yahoo Finance
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT),...
2 months ago
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate
Simply Wall Street
A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn.
2 months ago
Purple Biotech Advances in Oncology Drug Development - TipRanks.com
Tipranks
Purple Biotech Ltd. (PPBT) has released an update. Purple Biotech Ltd., a biotech firm trading on NASDAQ/TASE as PPBT,...
1 week ago
Purple Biotech (NASDAQ:PPBT) Rating Reiterated by HC Wainwright
Defense World
Purple Biotech (NASDAQ:PPBT – Get Free Report)'s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report...
2 weeks ago
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
GlobeNewswire
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 · Poster Details: Title: NT219, a dual inhibitor of IRS1/2 and STAT3,...
1 month ago
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster ...
Yahoo Finance
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study...
2 weeks ago
Purple Biotech's NT219 Shows Promising Cancer Fight - TipRanks.com
Tipranks
Purple Biotech Ltd. (PPBT) has released an update. Purple Biotech Ltd. has announced exciting developments for its cancer drug NT219,...
1 month ago
Purple Biotech to paint with Immunorizon's tri-specific antibodies in small M&A deal
Fierce Biotech
Purple Biotech is adding Immunorizon's tri-specific antibodies to its paint palette in an acquisition that could reach $100 million.
15 months ago